MedTrace Logo

Serum Rennin Kinetics Versus Serum Lactate Kinetics as Predictors of Mortality in Septic Shock Patients

NCT05327881 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-08-21

No results posted yet for this study

Summary

Whole blood lactate concentration is widely used in shock states to assess perfusion. We aimed to determine if the change in plasma renin concentration over time would be superior to the change in lactate concentration for predicting in-hospital mortality in septic shock patients.

Conditions

  • Septic Shock

Interventions

DIAGNOSTIC_TEST

Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.

Arterial blood gas samples, obtained at enrollment and at 24, 48, and 72 hours, were analyzed for lactate concentration using the ABL 800 series analyzer (Radiometer America, Brea, California, USA). Blood for these measurements was drawn into lithium-heparinized tubes. Lactate clearance was calculated at 24, 48, and 72 hours according to the following formula: Lactate Clearance (%) = \[(Baseline Lactate - Lactate at Time t) / Baseline Lactate\] × 100. An ELISA kit developed and manufactured by DRG International (Springfield Township, NJ, USA) was used to determine plasma concentrations of active renin. Blood samples were collected in EDTA tubes at baseline and at 24, 48, and 72 hours.. Plasma was separated from centrifuged samples and stored at -80°C for a maximum of 6 months until batch analysis. All samples were analysed in a single batch, and laboratory personnel were blinded to patient outcome. The assay was based on the sandwich ELISA principle

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Khaled A. AbdelRahman, Assistant professor · Assiut University

  • Nagwa M. Ibrahim, Professor · Assiut University

  • Abualauon M. Abedalmohsen, Lecturer · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05327881 on ClinicalTrials.gov